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1. Introduction 
Human immunodeficiency virus (HIV) infection is a pandemic that affects all parts of the 
globe. Current treatments fail to cure disease and for this reason there is significant interest 
in producing a vaccine to prevent HIV transmission, but clinical trials have proved 
disappointing. For this reason it is important to consider alternative measures to control 
incidence and prevalence of the disease. 
Trichomonas vaginalis is a highly prevalent and under-diagnosed sexually transmitted 
infection that facilitates transmission of and susceptibility to HIV infection (McClelland et 
al., 2007; Mavedzenge et al., 2010). Although current treatment is effective the disease is still 
poorly controlled and there are concerns about increasing levels of drug resistance (Upcroft 
& Upcroft, 2001). Efforts to research disease mechanisms and immune response with 
consideration to a rational vaccine design approach should be investigated as a potential 
method to reduce global incidence of T. vaginalis infection. 
A reliable murine model of T. vaginalis infection has been established with symptoms in 
female mice mimicking those seen in women (from vaginitis/vulvitis and discharge to 
asymptomatic but culture-positive for infection). Using this model it has been shown that 
vaccinating mice (by injection of trichomonad cells with adjuvant) protects the animals from 
subsequent vaginal infection (Abraham et al., 1996). By studying immune responses in mice, 
factors that are critical for immunological protection can be elucidated to create a 
“blueprint” for an effective human vaccine. 
Herein we provide an overview of the current understanding of T. vaginalis infection and 
epidemiology, methods of diagnosis and treatment, and implications of animal models for 
understanding disease mechanisms . We discuss how and why current T. vaginalis treatment 
protocols fail to control infection incidence with consideration as to how a T. vaginalis 
vaccine could overcome these obstacles and reduce disease burden. The association between 
T. vaginalis and HIV is examined and the potential for reducing HIV infection rates by 
lowering T. vaginalis incidence is elucidated.  
A vaccine against T. vaginalis would provide long term protection that could be more 
successful than treatment in controlling the spread of this very common disease. As T. 
vaginalis infection is a clear risk factor for HIV acquisition, it is our belief that this approach 
would also be effective in ameliorating HIV incidence and prevalence, especially in areas 
such as South and Southeast Asia and sub-Saharan Africa where HIV and T. vaginalis are 
endemic (United Nations, 2009; World Health Organization, 2001). 
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2. Trichomonas vaginalis 
2.1 Morphology 
The basic structure of T. vaginalis as reviewed in Petrin et al. (1998) and Heine & McGregor 
(1993) is best described as a 10-20 μm ovoid organism with four free-moving flagella located 
at the anterior portion, and one recumbent flagellum attached to the body of the cell by a 
membrane that forms an axostyle running longitudinally from the anterior portion to the 
posterior forming a pointed tip. The flagella and undulating membrane contribute to the 
organism’s characteristic jerky movements visualized under a common laboratory light 
microscope. Within the protozoan resides a nucleus with six chromosomes, a developed 
Golgi complex, but is devoid of mitochondria, peroxisomes or glycosomes, so instead 
contains hydrogenosomes typical of anaerobic protozoa and fungi. With respect to 
metabolic processes the parasitic nature of T. vaginalis owes to its inability to synthesize 
many nutrients and thus implicates a significant contribution of scavenged nutrients from 
hosts to survive (Heine & McGregor, 1993). 
2.2 Genetics 
Recently a draft genome sequence has been completed (Carlton et al., 2007) revealing a 
genome of approximately 160 Mb containing a core set of roughly 60,000 genes although it is 
suggested 39 Mb is repetitive genomic information as a result of enormous gene expansions. 
Important information will be derived from this data especially since gene regulation is not 
well understood and even now novel core promoter elements are being identified (Gomez et 
al., 2010; Smith et al., 2011) as well as hypothetical surface proteins from proteome analysis 
(de Miguel et al., 2010). Hypothetical surface proteins are of particular interest for 
extracellular parasites functioning to establish and maintain infection, and may shed light 
on current issues of classifying phenotypic differences for variable clinical presentation 
between hosts (Smith et al., 2011).  
2.3 Epidemiology 
T. vaginalis is an extracellular, anaerobic, parasitic protozoan that is the cause of 
trichomoniasis, the most common non-viral, curable STI with global incidence of at least 174 
million cases per year (WHO, 2001), likely an immense underestimation of actual incidence. 
Nevertheless, to put this number into relative terms of other curable STI the global incidence 
of syphilis, chlamydia and gonorrhoea as reported by WHO (2001) were 12 million, 92 
million and 62 million, respectively. The majority of cases are localized in regions of low 
income or lack of resources, especially health care. Other risk factors include Neisseria 
gonorrhoeae infection, Chlamydia trachomatis infection, risky sexual behaviours, older male 
partners (in terms of heterosexual couples), potential for non-sexual transmission by cultural 
habits such as shared bathing water, new or multiple sex partners, a history of STI, exchange 
of sex for payment, and drug use (Crucitti et al., 2011; Krashin et al., 2010; Sutton et al., 2007; 
Workowski & Berman, 2010). 
2.4 Trichomoniasis 
T. vaginalis resides in the squamous epithelium of the genital tract of both females and males 
with prevalence primarily within the reproductive years. General areas of infection in males 
include the urethra, external genitalia, prostate and epididymis. The vagina is the area most 
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commonly infected for females though it should be noted that other areas of infection 
include the Bartholin’s, Skene’s and periurethral glands, bladder and cervix (Heine & 
McGregor, 1993; Petrin et al., 1998). The infection is followed by an incubation period prior 
to onset of symptoms, if any at all, with persistent infection commonly occurring in females 
whereas eventual resolution occurs in males whom mostly serve as carriers and spread the 
infection to other partners (Petrin et al., 1998; Van Der Pol et al, 2005). 
A plethora of possible symptoms surrounds T. vaginalis infection. Rarely are all symptoms 
present nor are typical symptoms easily distinguishable from other urogenital infections. 
Additionally up to 50% of infected females and greater numbers in males are asymptomatic 
(Fouts & Kraus, 1980, as cited in Cudmore et al., 2004; Pastorek et al., 1996). While men and 
women usually present with malodorous discharge from the infected areas the most 
significant burden is found in women who may present with any of the following; high 
vaginal pH, bloody mucus, colpitis macularis, and vulvitis. Infection is associated with pelvic 
inflammatory disease, birth complications including premature rupture of the placental 
membrane, premature labour, low average birth-weight, and infertility, and increased 
transmission and contraction of HIV (Cotch et al, 1997; Mavedzenge et al., 2010; McClelland et 
al., 2008; Moodley et al., 2002; Pastorek et al., 1996; Wølner-Hanssen et al., 1989).  
2.4.1 Treatment of trichmoniasis 
Lossik (1990) describes the basics of metronidazole, a chemically modified form of the 
natural Streptomyces product azomycin from the family of nitroimidazoles, first synthesized 
in 1957 and finally marketed in 1960. Metronidazole is effectively administered as a single 2 
g dose or 500 mg twice daily for seven days with average cure rates of 96% and 92%, 
respectively. Side effects are minimal and more adverse effects are the result of  very high 
dosage and longer duration (Lossik, 1990). Upon diagnosis and treatment – typically 
females are diagnosed as male partners are less likely to observe or report symptoms – it is 
encouraged that sexual partners be tested and treated in concert as often these individuals 
are infected as well (up to 70% of male partners are also infected as reported by PCR testing 
in Seña et al., 2007). The treatment of trichomoniasis with this drug is highly effective 
although 5-10% of T. vaginalis isolates exhibit some degree of resistance as assayed in vitro 
(Upcroft & Upcroft, 2001).  
Five years after the discovery of metronidazole the first metronidazole-refractory case of T. 
vaginalis isolated from a female patient was reported by Robinson (1962, as cited in Lossick, 
1990). To avoid future difficulties with metronidazole resistance clinical and laboratory 
generated drug resistant isolates are under study to determine the mechanisms of resistance 
that can arise or have arisen (Upcroft & Upcroft, 2001). Alternatively, a T. vaginalis vaccine 
would sidestep the necessity to discover potential drug replacements in the event of 
epidemic resistance. 
2.5 Phenotypic variance of clinical disease 
In an attempt to define the phenotypic differences between clinical isolates causing 
symptomatic disease versus asymptomatic disease a number of areas are under 
investigation regarding host immune response and parasite-host interactions.  
2.5.1 Host immune response 
Scott et al. (2005) demonstrated that a symptomatic isolate of T. vaginalis induced only an IL-10 
response in dendritic cells while a more diverse IL-12, IL-10 and IFN-ǂ repertoire was 
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produced in response to selected infectious mucosal bacteria. Within the findings a potential 
relationship is noted between an IL-10 only response and chronicity of infection. IL-10 alone 
contributes to inhibition of T helper type 1 (Th1) immunity and favours a Th2 response 
(Banchereau et al., 2000, as cited in Scott et al., 2005). Similar results of a lack of IL-12 induction 
in macrophages were previously reported by Chang et al. (2004). On the other hand, cytokines 
related to Th1 type response (IL-2 and IFN-gamma) have been noted to be more prevalent in 
the sera of mice infected with asymptomatic isolates than symptomatic isolates (Malla et al., 
2007; Paintlia et al., 2002). Similar results have been found in other protozoal disease cytokine 
studies suggesting that in these cases Th1 mediated response may regulate disease and 
prevent overt clinical symptoms but not abolish infection (Agarwal et al., 1999,  Bayraktar et 
al., 2005 and Campbell & Chadee, 1997, all as cited in Malla et al., 2007). 
Yadav et al. (2005) investigated immunoglobulin kinetics of intravaginal trichomoniasis in a 
mouse model with asymptomatic and symptomatic clinical isolates. IgM, IgG (subclasses 1, 
2a, 2b and 3) and IgA were measured in serum and from vaginal washes from mice infected 
with asymptomatic and symptomatic isolates. Titers of IgG, IgG1 and IgM of vaginal wash 
and serum samples were significantly greater in symptomatic infected mice than 
asymptomatic mice, while IgA responses were not statistically different for serum or vaginal 
washes of either asymptomatic or symptomatic isolates. These results are mostly in line with 
vaginal wash data from symptomatic infections in women showing IgG and IgA at 
detectable levels versus undetectable levels in asymptomatic women (Alderete, 1984, as 
cited in Yadav et al., 2005). Data from Paintlia et al. (2002) found greater IgA levels in both 
vaginal wash and serum samples of asymptomatic isolates infected in mice contradicting the 
aforementioned findings. These results may indicate complications with the model of study 
or are simply the intricacies of trichomonal infection. Thus, some antibodies may provide a 
method of predicting the  severity of infection. Whether these findings are host dependent 
or mediated by phenotypic variance of T. vaginalis is yet to be elucidated. 
2.5.2 Parasite-host interactions 
Contact-independent mechanisms of damage correlated to symptomatic states of infection 
involve soluble factors shed from T. vaginalis including cell detaching factor (CDF), cysteine 
proteases and a haemolytic factor that is reliant on specific elevated vaginal pH in the range 
typically observed in clinical disease (Alderete & Garza, 1984; Fiori et al., 1996; Garber & 
Lemchuk-Favel, 1990). 
Gene regulation is influenced by contact with epithelial cells (Kucknoor et al., 2005) and 
cytoadherence has been noted as a better predictor of in vivo pathogenicity than cytotoxicity 
by soluble factors (Escario et al., 1995). Unfortunately the pathogenic role of adhesion 
proteins such as AP65, AP51, AP33 and AP23 that have been associated with epithelial cell 
binding of T. vaginalis (Alderete & Garza, 1984; Arroyo et al., 1992) have not conclusively 
been elucidated. Midlej & Benchimol (2010) suggests that adherence may aid phagocytic 
capability and disruption of monolayers in which T. vaginalis literally mechanically 
disassembles and phagocytoses membranes of epithelial monolayers in vitro similar to 
previous findings in amoebae and macrophages during ingestion of tumour cells (Chambers 
& Weiser, 1969, as cited in Midlej & Benchimol, 2010; Martinez-Paolmo et al., 1985, as cited 
in Midlej & Benchimol, 2010). Particularly, whole, viable cells are not phagocytosed yet 
destruction of epithelial cell layers is observed suggesting necrotizing ability of T. vaginalis. 
Interestingly within Midlej & Benchimol’s study (2010) an actin polymerization inhibitor 
significantly abrogated adherence while cytotoxicity remained relatively unaffected. 
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Another mechanism of interest is the availability of iron and its role in regulating immune 
evasion, and expression of adhesins and cysteine proteases (Lehker et al., 1991; Lehker & 
Alderete, 1992). Alternative pathway complement lysis allows destruction of trichomonads 
under low iron conditions assessed by Alderete et al. (1995). Upon supplementation of 
media with high levels of iron a cysteine proteinase capable of removing surface bound C3 
is upregulated. Still not all cysteine proteases are upregulated as found in Kummer et al. 
(2008). Herein, the data provides an inverse correlation of iron abundance and presence of 
CP2, CP3, CP4 and CPT (collectively referred to as CP30) which are involved in apoptosis of 
human vaginal epithelial cells. Kummer et al. (2008) suggests this particular apoptotic 
mechanism may play a role in iron acquisition and is self-regulating upon iron uptake. 
Alvarez-Sánchez et al. (2007) also provide a negatively regulated soluble factor, CP65, under 
high iron conditions. 
Understanding phenotypic variance will aid in understanding of the disease and elucidation 
of possibly novel mechanisms of regulation, as well as contribute to the strategies employed 
for development of a vaccine, a goal of ongoing research that will be discussed later. 
2.6 Diagnosis 
Before assessing the current diagnostic techniques available it is imperative to emphasize 
the difficulties of arriving at the diagnostic stage. Using a clinical syndromic approach a 
significant number of asymptomatic cases are missed. By not testing for nor treating 
asymptomatic infected individuals this enables the spread of disease and the lack of 
diagnosis results in underreported statistics of infection worldwide (Yin et al., 2008). 
Furthermore, in a prospective study Wiesenfeld & Macio (1999) found the available 
diagnostic tools such as simple wet mount microscopy, pH test or whiff test were often not 
used even under clinical suspicion of trichomoniasis. Ignoring the latter issue yet another 
problem arises. Diagnosis of cases investigated from clinical suspicion of trichomoniasis are 
at mercy of low sensitivity of current diagnostic standards as recent evaluations over the 
past decade have come to find (Lusk et al., 2010; Roth et al., 2011; Seña et al., 2007; Van Der 
Pol, 2007; Wendel et al., 2002). The most prevalent and most promising techniques will be 
reviewed below while a more detailed overview of guidelines for laboratory diagnosis and 
the methodology can be found in Domeika et al. (2010). 
2.6.1 Culture and wet mount microscopy 
Culture is considered the gold standard for diagnosis of T. vaginalis. Culture liquid is 
supplemented with antibiotics and samples are obtained from various locations such as 
vaginal/urethral discharge and swabs of known areas of infection. This technique requires 
as little as 102 trichomonads/mL (Garber, 2005). Unfortunately bacterial contamination 
remains an issue as well as lag growth phases of T. vaginalis. Additionally, this method is 
expensive and time consuming (Domeika et al., 2010) despite the availability of commercial 
culture systems (InPouch TV system: BioMed Diagnostics). Studies have found sensitivities 
ranging between 75-83% and specificity near 100% (Huppert et al., 2007; Nye et al., 2009; 
Wendel et al., 2002). 
Wet mount is an attractive diagnostic tool due to its simplicity and cost effectiveness, and is 
consequently the most widely used (Huppert et al., 2007). This technique requires that 
samples are placed in physiological sterile saline and kept warm for immediate viewing 
under a common laboratory microscope. Positive detection is assessed by visualization of 
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trichomonads exhibiting characteristic jerky movements (Domeika et al., 2010). Due to the 
requirement of at least 104 trichomonads/mL (Garber, 2005) this technique is not viable for 
urethral swab samples from males who typically yield low organism counts. Moreover, 
incorrect temperature or too much time elapsing between sampling and assessment results 
in loss of movement creating difficulty of differentiation from lymphocytes or nuclei of 
vaginal epithelial cells present in the sample (Garber, 2005). Sensitivities range from 52-
61.5% and specificity near 100% (Huppert et al., 2007; Nye et al., 2009; Van Der Pol et al, 
2006; Wendel et al., 2002). 
2.6.2 Nucleic acid amplification test and transcription mediated amplification 
Nucleic acid amplification testing (NAAT) and transcription mediated amplification (TMA) 
are recent, fairly labour intensive, highly sensitive but non-FDA approved diagnostic tools 
for detecting T. vaginalis which have been based on modifications of previous NAAT and 
TMA tests for infections such as chlamydia or gonorrhoea (Domeika et al., 2010; Van Der Pol 
et al, 2006). These tests may be conducted years after sample collection depending on proper 
storage conditions unlike wet mount which results in much less sensitivity unless 
maintained under strict time and temperature conditions (Van Der Pol et al, 2006). Despite 
high sensitivity for both male and female samples (Seña et al., 2007), greater than wet mount 
and culture (Crucitti et al., 2003; Lusk et al., 2010; Roth et al., 2011), in the range of 70-98% 
and specificity from 94-100% (Huppert et al., 2007; Nye et al., 2009; Seña et al., 2007; Wendel 
et al., 2002) this method is problematic as it is not point of care and remains unconfirmed for 
use in clinical settings. 
2.6.3 Rapid antigen testing 
Rapid antigen testing presents as probably the most promising technique despite requiring 
adequate technical skills and slightly less sensitivity than NAAT or TMA since it is 
inexpensive and can be employed at point of care (Domeika et al., 2010; Huppert et al., 
2007). Also, this diagnostic tool is more sensitive than wet mount and culture microscopy. 
The rapid antigen test employed in Huppert (2007) obtained a sensitivity of 90% and 
specificity of 100%. 
3. Murine model of infection and vaccination 
An effective model for the study of T. vaginalis is pertinent not only to understand the 
disease in context of the findings discussed so far, which only skim the surface of the actual 
breadth of scientific knowledge for each topic, but also to encourage development of vaccine 
strategies especially given the underestimated prevalence of the disease, the largely 
asymptomatic population group that remains untreated and the lack of available drug 
treatment in low resource settings. Within this frame of mind a mouse model modified to its 
current state by our lab holds important implications for study of T. vaginalis pathogenicity 
and also serves as a vaccination model. 
The murine model has been in development for some time coming to fruition as successfully 
demonstrating inducible protection upon vaccination against intravaginal challenge of T. 
vaginalis in BALB/c mice (Abraham et al., 1996).  
First, estrogenization studies in rats appear to affect APC presentation in vaginal cells and 
uterine stromal cells negatively while increasing antigen presentation in the uterine 
epithelial cells through mechanisms not thoroughly understood (Wira et al., 2000). 
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Nevertheless estrogenization is pivotal for increasing experimental infection rates in mice. It 
is hypothesized estrogenization may induce a state of estrus that is more permissive to 
infection (Meysick & Garber, 1992). This hypothesis is in line with results also within 
Meysick & Garber (1992) that infection rates were increased, but duration was unaffected, 
thus a factor at timepoint zero of infection likely mediates the findings. Additionally, in the 
same study the vaginal flora of the mouse remained unaffected by treatment, an important 
factor as we will see in other studies. Interestingly as a side note estrogenization in mice 
affects CDF, a soluble cytotoxicity element secreted by T. vaginalis (Garber et al., 1991). This 
may complicate findings when used as a disease model. 
Next, particular elements of the human vaginal environment have been thought to play a 
role in infection as noted by a decrease of Lactobacillus species levels and an associated 
increase of pH. Thus, through experimental inoculation of Lactobacillus acidophilus the mice 
would reflect more appropriately the human vaginal environment in terms of presence of 
lactobacilli and an associated pH decrease produced by products excreted by L. acidophilus 
(McGrory & Garber, 1992). With low percentages of natural incidence of lactobacilli in mice 
vaginas, an elevated pH and the disruption of these variables observed in human vaginas 
(Meysick & Garber, 1992) this factor of colonization was investigated. McGrory & Garber 
(1992) showed a significant increase in duration of trichomonal infection at day 24 post 
infection – 63-75% infected lactobacillus inoculated versus 0-25% infected controls. This 
suggests lactobacilli facilitate prolonged T. vaginalis infection. 
Finally, the vaccination model (see Abraham et al., 1996) utilizes subcutaneous whole cell 
vaccination emulsified in adjuvant. While unfortunately the current adjuvants used 
(Freund’s complete adjuvant and Freund’s incomplete adjuvant) are not safe for human use, 
current preliminary work with human-safe FDA approved adjuvant aluminum hydroxide 
(Alhydrogel) has shown induction of serum immunoglobulin responses significantly greater 
than natural infection (unpublished observations). While this result is not entirely surprising 
it simply adds to validation for use of the current mouse model as a candidate for 
experimental vaccine development. Furthermore these mice when infected fall into 
categories of asymptomatic and symptomatic infection. Of the latter, typical symptoms 
include vulvitis, vaginitis and vaginal discharge. 
Another similarity to human infection within the mouse model is that drug treatment 
resolution of infection and rechallenge does not confer any level of immune protection in 
mice as seen in humans (Abraham et al., 1996). On the other hand healthy skepticism is 
warranted in use of this current mouse model as suggested by Corbeil (1995). The actual 
pathogenic interactions of the murine vaginal epithelial cells with T. vaginalis are not 
characterized and similar protein binding adhesins mechanisms have not been 
demonstrated (Corbeil, 1995) which as previously noted was a significant correlate to 
symptomatic disease. Instead Corbeil suggests the use of a Tritrichomonas foetus bovine 
model.  
4. Vaccinating against trichomonads 
4.1 Bovine vaccine against T. foetus 
The T. foetus bovine model cattle are a natural host to the parasite and infection occurs 
through natural means. In addition to its well characterized disease states a commercial 
vaccine is already available (Fort Dodge Laboratories, Fort Dodge, Iowa) based on previous 
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work of immunization of bulls with whole cell or membrane fraction in oil adjuvant (Clark 
et al., 1983, as cited in Corbeil, 1995; Clark et al., 1984, as cited in Corbeil, 1995) and partial 
immunity in cows (Herr et al., as cited in Corbeil, 1995; Kvasnicka et al., 1989; Kvasnicka et 
al., 1992, as cited in Corbeil, 1995). The vaccines are not 100% protective, but significantly 
reduce transmission and infection rates among herds (Corbeil, 1995). Still this model may 
not be as attractive due to costs associated with purchase and husbandry of these animals 
whereas large sample numbers are obtainable, handling is easier and costs are within 
regular laboratory budgets to maintain mice. Also, while the host may be natural differences 
exist between T. vaginalis and T. foetus such as their ability to specifically induce lysis of 
human vascular endothelial cells and bovine vascular endothelial cells, respectively (Singh 
et al., 2004). As a last ironic note of difference it is the females that generally clear infection 
and the males that are asymptomatic carriers of T. foetus infection (Corbeil, 1995). 
4.2 Developing a human vaccine against T. vaginalis 
T. vaginalis presents an interesting challenge for providing immunity. It requires both 
mucosal immunity and consideration of mechanisms surrounding chronicity. Notably a 
vaccine obstacle is the surface heterogeneity of T. vaginalis inadvertently downregulating 
potent immunogenic proteins or glycoproteins (Alderete et al., 1986). Between phenotypic 
expression differences and strain differences between asymptomatic and symptomatic 
isolates an immunogen will be required to elicit robust immune response against a variable 
spectrum of antigens upon infectious challenge. The immunological activation necessarily 
must be sufficient enough to provide resolution without drug treatment especially in 
females. 
Theoretically speaking the approach may seem easy such as vaccinating against a protein 
involved in sequestering resources given the parasitic nature of the infection. Even if a 
recombinant immunogenic protein can be purified and produced consistently the delivery 
method is problematic as many routes of vaccination exist. While some routes are more 
desirable than others, depending on the adjuvant of choice the options to produce an 
appropriate response via a given route become far and few between. While applying our 
expanding knowledge of adjuvant mechanisms and adjuvant-mediated immune response 
skew (O’Hagan & De Gregorio, 2009) may seem an obvious path, it neglects to consider the 
importance of understanding of the infection processes that mediate immune evasion or are 
the reason natural immunity fails in the first place. This gap emphasizes our need for a 
consistent laboratory model for study of pathogenesis and the mechanisms of function to 
facilitate adjuvant selection and even antigen selection as a subunit vaccine alone may not 
work. Lastly, in design of a vaccine we must consider the target demographic. In this case 
there is a strong need to service low resource communities especially those sub-Saharan 
Africa areas with high incidence and prevalence of both T. vaginalis and HIV infection 
(World Health Organization, 2001). 
Progress in development of a bovine vaccine rather than a human vaccine has been strongly 
driven by economical factors of commercial farming involving loss of calves in utero 
(Kvasnicka et al., 1989). If it is commercial revenue or cost associated with the disease that 
drives funding for research then one must consider the 1.52-2.05 fold increased risk of HIV-1 
acquisition (Mavedzenge et al., 2010; McClelland et al., 2008) and the costs associated with 
drug therapy of both trichomoniasis and HIV.  
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5. Rationale for a human T. vaginalis vaccine 
5.1 Failure to control T. vaginalis with current treatment 
The current treatment for trichomoniasis is oral metronidazole or tinidazole, either as a 
single 2g dose, or 500mg twice a day for 5 to 7 days (WHO, 2003). Treatment of a patient's 
current sexual partners has often been recommended but there is some question as to the 
efficacy of partner therapy. The Centers for Disease Control and Prevention (CDC) do not 
recommend patient delivered partner treatment (PDPT) for trichomoniasis as they have not 
found sufficient evidence that PDPT significantly impacts rates of T. vaginalis infection 
(Centers for Disease Control and Prevention, 2006). Additionally, there are barriers 
associated with PDPT. Having multiple partners or a new partner are predictors for 
trichomoniasis (Peterman et al., 2006), so PDPT may be ineffective as it may be difficult or 
undesirable to provide multiple partners with treatment, and a partner obtained after 
treatment has been completed obviously could not have been the source of initial infection 
and therefore will not receive treatment. Additionally, a study of HIV positive women who 
were provided with PDPT showed that 25% did not deliver treatment to their partners. 
Reasons for not delivering medication included being unable to contact a partner, not 
wanting to see a partner again, and being afraid of a partner's reaction. Fear of a partner's 
reaction was not limited to revealing T. vaginalis infection, but was also associated with 
having a partner who was unaware of the woman's HIV infection status (Gatski et al., 2010). 
This is particularly disturbing in light of the fact that the presence of T. vaginalis can lead to 
an increased risk of the partner contracting HIV, while at the same time ignorance about 
HIVpositive status may mean that the partner is more willing to engage in unprotected sex.  
Because trichomoniasis is endemic in resource-limited settings, diagnosis is generally made 
purely on the basis of symptoms without any clinical testing. Syndromic treatment then is 
prescribed based on the most likely cause of illness. Because the symptoms of T. vaginalis 
infection are similar to other non-ulcerative STIs (urethritis in men, vaginitis and discharge 
in women) (Petrin et al., 1998) the disease is frequently misdiagnosed and the inappropriate 
drug is prescribed. Despite of the fact that WHO guidelines indicate metronidazole or 
tinidazole therapy is recommended in all cases of vaginal discharge (WHO, 2003), 
trichomoniasis is still under-diagnosed and under-treated.  
A study in India showed that using the relatively inexpensive InPouch culture kit to test for 
T. vaginalis at the point of care increased would have increased the correct treatment of 
trichomoniasis from 51% (syndromic treatment, no testing performed) to 82% (based on 
InPouch results) (Madhivanan et al., 2009). Unfortunately, culture testing requires 3 to 7 
days of incubation to confirm the presence or absence of trichomonads, and this time frame 
may not be acceptable to patients who need to travel to reach medical facilities. 
Another problem with syndromic management of trichomoniasis is that treatment 
guidelines are clear for women only. In India, a country where metronidazole treatment for 
vaginal discharge is part of syndromic management, high rates of T. vaginalis infection were 
still found in women, and also in many men. Current guidelines recommend treating for 
trichomoniasis in men only if symptoms of urethritis persist after treatment for gonorrhoea 
and chlamydia (WHO, 2003). Introducing metronidazole as a part of syndromic treatment 
for men presenting with non-ulcerative genital infection has been recommended (Becker et 
al., 2010), however this will still not address the problem of asymptomatic carriers. 
Poor control of trichomoniasis is not solely a problem in developing countries. A study in 
the United States showed that the prevalence of T. vaginalis infection is approximately 3% in 
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women between the ages of 14 and 49. This infection rate doubles in the poorly educated 
and economically disadvantaged, and nearly quadruples in black women (Allsworth et al., 
2009). Additionally persistent, subclinical T. vaginalis infections have been reported even 
after seemingly successful treatment. A study on HIV positive women diagnosed with 
trichomoniasis showed that despite reported compliance with metronidazole treatment 
regimen and putative successful cure (negative InPouch culture), a number of women tested 
positive for T. vaginalis infection 3-6 months later, despite reporting no sexual contact in the 
intervening time (Gatski & Kissinger, 2010).  
Drug resistance to nitroimidazoles such as metronidazole and tinidazole has also been 
reported in 5-10% of clinical specimens (Upcroft & Upcroft, 2001). As there are currently no 
effective non-nitroimidazole treatments for trichomoniasis, drug resistant T. vaginalis must 
be treated by increasing medication dosages, which often leads to increased adverse effects. 
If these adverse reactions become severe enough to force cessation of therapy, 
trichomoniasis can become a chronic condition (Cudmore et al. 2004). 
5.2 Other issues with treatment to control T. vaginalis 
Sexually transmitted infections such as trichomoniasis are societal as well as medical 
problems. In order to successfully control the disease the personal, social, and cultural 
barriers associated with dealing with STI need to be addressed. 
5.2.1 The education risk factor 
Accurate and useful information on STI can be difficult to obtain. A study done with 
students (aged 13-16, male and female) in the United Kingdom showed that STI were 
recognized as a serious health problem. However, many of the teenagers were ill- or 
misinformed about the names of common STI, how to identify a possible infection, where to 
seek treatment, etc. (Garside et al., 2001). Lack of education has clearly been shown to be a 
risk factor for acquiring STI. Unfortunately education programs are not available in many 
areas where HIV and trichomoniasis are endemic due to reasons such as lack of finance and 
resources, geography, and cultural or personal discomfort about discussing sexuality and 
STI. As such, the importance of protecting those with little opportunity to access 
information about STI cannot be underestimated. 
Lack of information and awareness regarding STI has been shown to lead to delays in 
seeking treatment for medical issues involving the genitals. Participants in a study in rural 
Zimbabwe had little awareness that having an STI could increase their risk of contracting 
HIV. Men were more aware of the link between STI and HIV (18% of men vs 5 % of women) 
and this knowledge was associated with seeking treatment more promptly upon noticing 
symptoms of genital disease. However many men (36%) and the majority of women (70%) 
ignored symptoms of urethral/vaginal discharge or discomfort, or lower abdominal pain 
for a week or more before seeking treatment (Gregson et al., 2001). Given the fact that 
trichomoniasis and other STI have been linked to sequelae such as infertility and adverse 
pregnancy outcomes, delays in seeking treatment puts reproductive health at risk. 
Education about STI in the general population is not the only issue, part of the problem can 
stem from the lack of healthcare workers specialized in dealing with sexual issues and 
diseases. In many parts of the world specialist physicians are rare and general practitioners 
may not have sufficient background, or simply not be comfortable discussing "intimate" 
issues, especially with the opposite sex. Women are often more comfortable dealing with 
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other women when discussing sexual issues, but a study in Bangladesh found that  female 
healthcare workers were often uncomfortable discussing sexuality or performing genital 
exams (Gibney et al., 1999). Because of the embarrassment, social implications, etc. often 
attached to the subject of STI, an open discussion between a patient and healthcare provider 
can be difficult when medical personel are clearly uncomfortable with the subject. Patients 
may be less forthcoming about their symptoms and less likely to seek treatment if healthcare 
workers appear to be judgemental or reluctant to provide information and care. 
5.2.2 Cultural barriers 
There is a nearly universal stigma attached to having an STI. Sex and sexuality are generally 
considered to be very personal issues and seeking treatment for genital disease involves 
speaking about private matters. In addition reluctance to seek treatment can stem from fear 
of being associated with promiscuity and negative social behaviours, which are often linked 
with STI. A study of pregnant women in India showed that although the majority of women 
stated they were willing to be tested for HIV, they were also highly concerned about the 
reactions of their husbands, families, and community should it be found that they were 
seropositive. Additionally, not breastfeeding (recommended to prevent maternal-child HIV 
transmission) was widely believed to be a sign that a woman was a bad mother or had been 
unfaithful to her husband (Rogers et al., 2006). 
Women in particular are often reluctant to speak about genital health issues, one study cites 
"shyness" as the single biggest barrier in seeking STI treatment (Gibney et al., 1999). A study 
of pregnant women in Nairobi found that over a quarter of women refused to answer 
portions of a health questionnaire related to vaginal discharge. Of the women who did 
respond, only 6% complained of discharge, but 51% were found were found to have 
abnormal vaginal discharge on clinical examination (Marx et al., 2010). Another study, also 
in pregnant women, found that although many of the women questioned recognized a 
variety of symptoms (including vaginal discharge/itching, dysuria, and genital ulcers or 
swelling) only 9% sought treatment (Blankhart et al., 1999). This statistic is particularly 
disturbing in view of the adverse outcomes associated with having an STI during 
pregnancy. Reluctance to seek STI treatment for fear of negative reactions from family 
and/or community is putting both child and maternal health at risk. 
5.2.3 Sexual inequality and risk 
Sexual risk behaviour in women has been found to significantly influence their likelihood of 
contracting trichomoniasis, but not HIV. Conversely high risk (male) partner behaviour 
significantly increased the female partner's risk of acquiring HIV, but was not associated 
with increased incidence of trichomoniasis (Mavedzenge et al., 2010). This issue of male 
sexual risk behaviour contributing to a female partner's risk of acquiring an STI, especially 
HIV, is important because many women do not have complete control of their sexual 
activities. A study of 481 pregnant young women in the Central African Republic showed 
that 72% reported voluntarily engaging in their first sexual intercourse, 18% were pressured 
their first intercourse, and 11% reported their first sexual intercourse was a rape. With 
respect to their pregnancies, 52% reported their pregnancy was planned and desired, 32% 
reported unplanned but accepted, and 16% reported that they did not desire the pregnancy 
(Blankhart et al., 1999).  
A study on risk factors for HIV acquisition in Africa found that women's sexual choices are 
often limited or dictated by their male partners. Some women reported that they were 
www.intechopen.com
 
HIV-Host Interactions 310 
forced into a sexual relationship as it was their only means to obtain food, shelter, or money 
for education. Others stated that they required their partner's permission to obtain medical 
care (including HIV testing) and to protect themselves (ie. use condoms). Marital standards 
are also unbalanced as while married women are expected to remain faithful to their 
husbands, men are not necessarily expected to maintain complete fidelity, especially if they 
are away from their wives (Chersich & Rees, 2008).  
In many rural areas labourers must migrate to different locations or into cities to find work. 
This can result in significant periods of spousal separation and can result in one or both 
partners seeking extra-marital sexual intercourse. A study in Zimbabwe showed that while 
both partners may visit "beer halls" women are at statistically significant increased risk of 
HIV acquisition, while only a small non-significant increase in risk was seen for men 
(Gregson et al., 2001). In China, a study of migrant workers of both sexes found that they 
often engaged high risk sexual behaviours much more than the general population. In 
particular women were more likely to sell sex for money and men more likely to pay for sex. 
Interestingly, this increased involvement with the sex trade increased the prevalence of STI 
and HIV in women, but no statistically significant increase seen in men (Wang et al., 2007). 
5.2.4 Marginalized populations 
Female sex workers (FSW) are unsurprisingly at a high risk for STI. They can also act as a 
reservoir for STI that can be difficult to deal with using treatment alone as they can be 
sexually active on a daily basis. Additionally studies like one in Indonesia have shown that 
STI rates are highest in FSW in the lowest socioecomonic class, who charge the lowest prices 
per sex act and as such need to see more clients, increasing their risk for STI. These women 
are also more likely to have little ability to negotiate condom use, and have minimal money 
to spend on medical care and medication (Joesoef et al., 1997). 
Even when healthcare initiatives aimed at FSW are in place, education and medical care are 
still not necessarily easily available to all. This is especially true for FSW who are non-
residents or illegal immigrants in the country in which they are working. A study in Sydney, 
Australia showed an impressively low rate of STI amongst "local" FSW (women who were 
native Australian or had been in the country a significant period, and English-speaking) 
after partial legalization of the sex trade and an aggressive education campaign. However 
"international" FSW (women born outside of Australia whose first language was not 
English) showed high rates of STI. Language barriers, lack of access to the same medical 
programs as residents, and concerns about drawing attention to themselves by accessing 
medical care meant that these women remained at high risk despite there being a system in 
place to help protect them (O'Connor et al., 1996). 
Sex trade workers are clearly an excellent target population for a vaccine that could provide 
long term, consistent protection from T. vaginalis infection and offer a reduced risk of HIV 
acquisition. They are part of a "core" group that acts as a reservoir for STI, and reducing the 
burden of infection in this population can be a community benefit.  
5.3 Advantages of a vaccine for prevention of T. vaginalis infection 
Trichomoniasis can be treated relatively easily and inexpensively, yet the disease is poorly 
controlled. Diverse factors lead to both a failure to recognize T. vaginalis infection and 
inability or unwillingness to seek or access treatment. A vaccine could provide long term 
protection eliminating the need for repeated doctor visits and treatments, the risk of 
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misdiagnosis, and address the needs of high risk populations. In addition, given the link 
between trichomoniasis and other genital infection, especially HIV, a vaccine capable of 
preventing T. vaginalis infections has the potential to impact global STI burden. 
6. T. vaginalis and HIV 
6.1 Incidence and prevalence of trichomoniasis and HIV 
It is estimated that approximately 33.3 million people are currently infected with HIV-1. 
About two-thirds of these (22.5 million) are living in sub-Saharan Africa and 4.1 million live 
in South and Southeast Asia (UN, 2009). Both these areas also have the highest rates of T. 
vaginalis infection, with about 32 million cases in sub-Saharan Africa and 76.5 million in 
South and Southeast Asia every year (WHO, 2001). Global rates of trichomoniasis and HIV 
tend to follow similar patterns in different areas of the world (ie. the higher the incidence of 
T. vaginalis infection, the higher the prevalence of HIV) with two exceptions. As stated 
above, sub-Saharan Africa has the highest prevalence of HIV and the second highest 
incidence of trichomoniasis, while the opposite is true for south and Southeast Asia. The 
other exception is North America, which has a fairly high prevalence of HIV (1.5 million 
cases) (UN, 2009) relative to a low incidence of T. vaginalis infection (8 million annually) 
(WHO, 2001). 
Rates of co-infection with HIV and T. vaginalis in women have been reported to range from 
16% to almost 30% (Allsworth et al., 2009; Gatski et al., 2010; Månsson et al., 2010; Marx et 
al., 2010). It is difficult to reliably estimate co-infection rates in men as trichomoniasis is 
generally asymptomatic and not usually considered a significant STI in males. 
6.2 T. vaginalis and increased risk of HIV transmission 
Trichomoniasis has been associated with a 1.52 to 2.05 times greater risk of seroconversion 
upon exposure to HIV (McClelland et al., 2007, Mavedzenge et al., 2010). A longitudinal 
study of almost 5000 women in South Africa and Zimbabwe showed that the link between 
HIV and T. vaginalis appears to be bi-directional. Compared to uninfected women, those 
with trichomoniasis were more likely to test positive for HIV at their next study visit, and 
HIV positive women were more likely to have acquired T. vaginalis infection by their 
following study visit (odds ratios were >2 for both cases, after adjusting for confounders 
such as age, other STIs, and sexual risk behaviours) (Mavedzenge et al., 2010). This leads to 
an increased risk of both T. vaginalis and HIV infection if both diseases are present in any 
combination between sexual partners. 
6.2.1 Disruption of genital mucosa 
As previously mentioned, T. vaginalis is capable of both contact dependent and contact 
independent disruption of cell layers (see section 2.5.2). This disruption can provide portals 
of entry that allow HIV access past the epithelium into tissue, can sometimes lead to the 
formation of punctuate mucosal hemorrhages (strawberry cervix) women. 
Without co-factors such as STI co-infection or trauma to the genital mucosa, the odds of a 
woman acquiring HIV through sexual exposure are estimated to be 0.08%. The odds of 
female to male transmission are 0.04% per exposure. Healthy, intact genital mucosa is 
considered to be a significant barrier to HIV infection (Thurman & Doncel, 2011). Because 
trichomoniasis can disrupt the integrity of mucosal tissue this primary barrier against 
infection is breached and HIV transmission risk is increased. 
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The degree of epithelial disruption has been found in vitro to vary between different isolates 
of T. vaginalis. A study examining four different T. vaginalis clinical isolates (two from 
asymptomatic patients and two from symptomatic patients presenting with cervicitis and 
vaginal discharge) found that the symptomatic isolates rapidly disrupted cell monolayers, 
but the asymptomatic isolates had a much more limited effect on monolayer integrity. The 
potential impact of monolayer disruption on the ability of HIV to enter tissue was examined 
by adding HIV and T. vaginalis to the apical surface of stratified monolayers growing on 
transwell plates, then measuring the amount of virus present in the basolateral supernatant. 
The degree of monolayer disruption was found to correlate with the amount of HIV released 
into the basolateral supernatant. Symptomatic isolates (disrupted monolayers) caused a 
four- to five-fold increase in HIV released into supernatant, whereas asymptomatic isolates 
(intact monolayers) showed HIV supernatant levels similar to background (no trichomonads 
on monolayers) (Guenthner et al., 2005). Although only four isolates were used, this 
experiment suggests that not all isolates of T. vaginalis may have equal impact on the risk of 
acquiring HIV infection. This is an intriguing possibility that could potentially offer some 
explanation as to why the high incidence of trichomoniasis in South and Southeast Asia is 
not matched by an equally high prevalence of HIV. 
6.2.2 Changes to vaginal flora 
Both trichomoniasis and HIV transmission have been linked to disrupted or abnormal 
vaginal flora. A study examining the link between T. vaginalis infection and bacterial 
vaginosis (BV) showed that 61% of HIV positive women also had BV and 80% had abnormal 
vaginal flora (defined as Nugent scores of 7-10 and 4-10, respectively). In comparison HIV 
negative women with trichomoniasis showed 47.3% incidence of BV co-infection, and 58.9% 
had abnormal vaginal flora (Gatski et al., 2010). However, since co-infection with 
trichomoniasis and BV is relatively common, it is difficult to tell which, if either, infection 
acts as the primary risk factor. 
Both trichomoniasis and BV are associated with an increase in vaginal pH and decreased or 
absent vaginal Lactobacillus species (Petrin et al., 1998 (trichomoniasis) and Sha et al., 2005 
(BV)). Lactobacilli produce lactic acid which maintains the low pH of the (healthy) vagina. 
Lactic acid has been shown in vitro to inactivate HIV, as has H2O2 which is produced by 
some, but not all, lactobacilli (Klebanoff et al., 1991). Lactobacilli therefore contribute 
maintaining a vaginal milieu that is not permissive to infectious agents, and loss of 
Lactobacillus species can lead to increased chances of STI. Low vaginal pH and H2O2 can also 
inhibit activation and proliferation of vaginal lymphocytes, particularly CD4+ T cells (Hill & 
Anderson, 1992). This means that disruption of the vaginal environment by T. vaginalis can 
lead to greater risk of HIV infection due to an increase of activated CD4+ T cells that can be 
infected by the virus. 
6.2.3 Inflammatory response 
Infection with T. vaginalis leads to a local inflammatory response that includes 
chemoattractant (IL-8) and acute pro-inflammatory (TNF-ǂ ,IL-1ǃ, and IL-6) cytokines that 
are responsible for initiating immune response to infection and recruiting immune cells. 
Symptomatic infection is the result of a more vigorous immune response in which there is 
an increased amount of inflammation and cell recruitment. For example, in women vaginal 
discharge often contains neutrophils that respond to the presence of IL-8 (Thurman & 
Doncel, 2010). However immune response may fail to clear T. vaginalis, and does not 
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provide long term immunological memory to prevent subsequent infections. Additionally 
immune response to trichomoniasis can attract lymphocytes that are the targets of HIV 
infection. 
A powerful chemoattractant, IL-8 recruits immune cells to where they are needed to 
eliminate infection. However, it has also been shown that this cytokine can increase the 
susceptibility of monocytes, macrophages, and CD4+ T cells to HIV infection. IL-8 can also 
enhance HIV replication in infected immune cells (Narimatsu et al., 2005). 
A study using cervicovaginal lavage samples from HIV positive women who were also 
infected with T. vaginalis showed elevated levels of IL-1ǃ. Levels of IL-1ǃ could be 
significantly different between visits, but clearly correlated with HIV viral load (Mitchell et 
al., 2011). 
An in vitro study using HIV-infected peripheral blood mononuclear cells (PBMC) cultured 
with T. vaginalis resulted in increased replication of HIV compared to PBMCs alone. Unlike 
epithelial cell disruption, different isolates (symptomatic or asymptomatic) seemed to 
induce similar levels of increase in HIV replication. It was found that TNF-ǂ levels were 
elevated in the supernatant of cultures containing T. vaginalis compared to controls and the 
addition of anti-TNF-ǂ antibody could attenuate the increase in HIV replication (Guenthner 
et al., 2005). 
The relationship between IL-6 and HIV is interesting in that they seem to be capable of 
upregulating each other in an apparent positive feedback loop. Examination of ectocervical 
tissue from HIV positive women found higher levels of IL-6 than in uninfected controls. 
Because the ectocervix was an area where high levels of HIV replication had been detected, 
recombinant IL-6 was applied to tissue explants and a greater than 300-fold increase in HIV 
transcription was seen (Asin et al., 2009). HIV appears to be capable of not only infecting 
immune cells, but of using immune response to its own advantage to enhance its replication.  
6.2.4 Increased viral load 
Inflammatory response to T. vaginalis infection leads to an influx of susceptible lymphocytes 
and the release of cytokines that can upregulate the rate of HIV replication. This in turn can 
increase HIV viral load and lead to a higher risk of spreading the infection to unprotected 
partners. A study looking at HIV positive men with genital ulcers found HIV RNA 
increased in ulcers caused by herpes simplex virus type 2 (HSV-2) only if HSV-2 was 
present in the ulcer. However, co-infection with T. vaginalis increased HIV viral load in 
ulcers regardless of the presence of HSV-2 indicating that trichomoniasis leads to increased 
shedding of HIV regardless of (or perhaps even in synergy with) other STI (Paz-Bailey et al., 
2010).  
While trichomoniasis does increase the amount of HIV viral shedding, elimination of T. 
vaginalis infection returns HIV RNA levels in the genitals to lower levels. A study in Africa 
of HIV positive women with trichomoniasis measured viral RNA at the time of trichomonal 
infection, and then 2 weeks later after treatment when infection had been resolved. There 
was a 4.2 fold decrease in the amount of HIV shed (Wang et al., 2001). Another study in 
New Orleans examined vaginal viral shedding in HIV positive women with and without 
trichomoniasis. Women with T. vaginalis infection were almost twice as likely as women 
without trichomoniasis to have detectable HIV RNA in their vaginal secretions at baseline 
(36.2% vs 19.6%). One month following successful treatment for trichomoniasis, the number 
of women shedding HIV was reduced (although it remained significantly higher than in 
women previously uninfected by T. vaginalis). At followup visits three months after initial 
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interviews there was no significant difference in the number of women shedding vaginal 
HIV between the two groups (Kissinger et al., 2009), indicating that elimination of the 
parasite removes the enhanced HIV risks associated with trichomoniasis. As T. vaginalis 
clearly has a significant impact on HIV infection, reducing incidence of trichomoniasis has 
the potential to help control the incidence and prevalence of HIV. 
6.3 Reducing T. vaginalis as a method of HIV prevention 
Trichomoniasis is clearly associated with HIV risk, the question is can reducing T. vaginalis 
infections have an impact on the incidence of HIV? A study in Tanzania showed that a 
decrease in HIV prevalence in women was accompanied by a significant decrease in 
multiple STI, particularly trichomoniasis which dropped from 21.2% to 5% incidence over 
the 3-5 year cross-sectional study. This reduction in disease burden was attributed mainly to 
changes in sexual behaviour as a result of a multi-pronged sexual health awareness 
campaign. Interestingly very little change was seen in condom use or age of first sexual 
intercourse, but a dramatic decline was seen in women reporting having engaged in casual 
sex (Msuya et al., 2007). As a women's sexual risk behaviour is correlated with the risk of 
trichomonal infection, this study suggests that protecting women from T. vaginalis could 
contribute to protecting them from HIV. Since treatment has proved to be an ineffective 
method of reducing trichomoniasis, a vaccine could provide long term for protection to 
those who are both most at risk and least able to protect themselves. 
A vaccine would also be helpful in targeting specific at risk populations. For example, black 
women have consistently been shown to have a higher incidence of trichomoniasis than 
women of other races (Shafir et al., 2009). This may be the result of sample bias, as many 
studies take place in inner-city clinics and in sub-Saharan Africa where other risk factors 
such as poverty and lack of education are also present. It could also be the result of certain 
common practices (eg. vaginal cleaning/douching), unknown biological factors, or a 
combination of factors that act synergistically to increase susceptibility to T. vaginalis 
infection. The availability of a vaccine could target protection to those with increased risk, 
while avoiding stigmatizing a specific population. As this population has also been found to 
have an increased risk of HIV infection, an single effective vaccine could potentially have a 
significant impact on the incidence of both diseases. 
HIV and the spectrum of medical issues that arise from infection are complicated issues that 
are often not well understood by either the HIV positive or the HIV negative. For example, 
many people believe if an HIV-positive person has an undetectable viral load, that they 
cannot infect anyone else. However, it has been shown that up to 33% of women with 
undetectable serum viral load continue to shed the virus in cervicovaginal secretions (Neely 
et al., 2007). Due to high rates of co-infection with T. vaginalis it is likely that a number of 
these women have or will acquire trichomoniasis. A T. vaginalis vaccine could reduce the 
burden of disease in HIV positive individuals who are at high risk to acquire trichomoniasis, 
and protect their partners from the elevated risk associated with co-infection. 
7. Conclusions 
Current methods for reducing the incidence of HIV include education and public health 
programs (providing condoms and encouraging condom use, needle exchange, etc.) and 
antiretorviral therapy (ART) to reduce HIV viral titers and minimize the risk of 
transmission. However, HIV is endemic in developing countries where obtaining resources 
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(financial, personal, etc.) and accessing (may need to travel from rural areas to cities) 
education and health programs can be difficult, potentially limiting positive impact. 
Providing ART also poses a problem in resource limited settings as it is an expensive multi-
drug cocktail and therapy is often complicated by drug interactions and toxicity, and 
adverse patient reactions. Additionally, ART is usually prescribed based on CD4+ T cell 
count, and monitoring can be difficult if patients must travel to reach a medical facility 
capable of testing (WHO, 2006). Finding simple, inexpensive alternative methods to reduce 
the transmission of HIV could help reduce dependence on ART as a means of controlling 
HIV incidence.  
Treatment of STI can be difficult for reasons beyond drug availability and efficacy and 
access to healthcare. Cultural barriers and personal beliefs can affect an individual's 
acceptance of their diagnosis and willingness to seek treatment. Limited control over one's 
sexual activity can lead to an inability to protect oneself and control sexual risk. In addition, 
some populations (eg. FSW) are at a persistently higher risk for STI and while treatment 
eliminates disease, it does not protect against subsequent infection thus will have minimal 
impact on STI incidence. The development of a T. vaginalis vaccine that could be offered as 
part of routine medical care for high risk groups could eliminate the need to seek treatment, 
reduce risk, and lower the incidence of trichomoniasis. 
T. vaginalis infection has been shown to facilitate both transmission and acquisition of HIV 
through multiple mechanisms. Many of these mechanisms have been described in vitro, but 
their exact correlation to infection is not clearly defined. The existence of a mouse model of 
T. vaginalis infection provides a powerful and relatively inexpensive tool to elucidate the 
disease mechanisms of trichomoniasis in vivo. The model also allows for the evaluation of 
immune responses to T. vaginalis infection and vaccination as a part of an approach to 
rational vaccine design. 
The actual increase in risk of acquiring HIV or infecting a sexual partner due to 
trichomoniasis is unknown. However, given that the high incidence of T. vaginalis infection 
(174 million cases annually), the fact that it is globally distributed in similar patterns to those 
of HIV, and that some populations have been found to have co-infection rates as high as 
almost 30% (Allsworth et al., 2009), even a small percentage of T. vaginalis infections leading 
to seroconversion could significantly impact the incidence of HIV. Vaccination against T. 
vaginalis offered to "core" groups that act as reservoirs of STI could have the potential to 
reduce community incidence of both trichomoniasis and HIV. Pregnant women are also 
often at increased risk of trichomoniasis due to hormonal changes. Vaccinating against T. 
vaginalis would not only prevent adverse birth outcomes associated with trichomoniasis, but 
could potentially protect against an HIV infection that could lead to maternal-child 
transmission of the virus. Thus, we suggest vaccination against T. vaginalis as an alternative 
approach to HIV control as well as for prevention of this highly prevalent STI. 
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